Prior to stem cell transplantation to a patient, the existing disease must be eradicated. Therefore, patients undergo conditioning regimens to eliminate, in the case of blood cancers, all or most of the tumor cells. This also destroys the patient’s blood generating (hematopoietic) system. Following conditioning, stem cells either derived from the patient’s own system (autologous) or from a matched donor (allogeneic) are introduced to the patient to renew the hematopoietic system.
“These data solidify the role of ZEVALIN in treatment regimens for lymphoma patients,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals, Inc. “These presentations confirm our belief that ZEVALIN will continue to show strong data in a range of protocols to prepare lymphoma patients for these life-saving procedures.”
Tuesday, December 7, 2010
Stem Cell Transplantation in Treatment of NonHodgkins Lymphoma, SPPI Stem Cell Stock
See this Amp at http://bit.ly/gzE8lO
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment